Your browser is no longer supported. Please, upgrade your browser.
Settings
CELG Celgene Corporation daily Stock Chart
CELG [NASD]
Celgene Corporation
IndexS&P 500 P/E16.39 EPS (ttm)5.53 Insider Own0.10% Shs Outstand699.18M Perf Week3.16%
Market Cap63.41B Forward P/E7.23 EPS next Y12.55 Insider Trans-3.25% Shs Float698.08M Perf Month3.88%
Income4.05B PEG0.94 EPS next Q2.51 Inst Own74.60% Short Float2.17% Perf Quarter29.11%
Sales15.28B P/S4.15 EPS this Y109.10% Inst Trans-2.26% Short Ratio1.45 Perf Half Y1.59%
Book/sh6.92 P/B13.11 EPS next Y17.09% ROA8.50% Target Price98.40 Perf Year-3.92%
Cash/sh6.26 P/C14.48 EPS next 5Y17.52% ROE54.90% 52W Range58.59 - 97.43 Perf YTD41.50%
Dividend- P/FCF18.84 EPS past 5Y25.80% ROI20.00% 52W High-6.92% Beta1.74
Dividend %- Quick Ratio2.00 Sales past 5Y18.70% Gross Margin96.20% 52W Low54.79% ATR1.49
Employees7467 Current Ratio2.10 Sales Q/Q18.40% Oper. Margin26.10% RSI (14)68.89 Volatility1.97% 1.67%
OptionableYes Debt/Eq4.17 EPS Q/Q24.00% Profit Margin18.30% Rel Volume0.77 Prev Close90.68
ShortableYes LT Debt/Eq4.06 EarningsJan 31 BMO Payout0.00% Avg Volume10.47M Price90.69
Recom2.30 SMA203.11% SMA5014.42% SMA20010.95% Volume8,134,592 Change0.01%
Feb-01-19Downgrade Jefferies Buy → Hold $95
Jan-04-19Upgrade Robert W. Baird Neutral → Outperform
Jan-04-19Upgrade Goldman Sell → Neutral
Dec-21-18Resumed BTIG Research Neutral
Oct-01-18Initiated Cantor Fitzgerald Overweight $100
Jun-18-18Upgrade Standpoint Research Hold → Buy
May-29-18Reiterated SunTrust Hold $106 → $96
May-23-18Upgrade Bernstein Mkt Perform → Outperform
May-23-18Downgrade Argus Buy → Hold
May-07-18Downgrade RBC Capital Mkts Top Pick → Outperform
Apr-13-18Resumed Morgan Stanley Equal-Weight $93
Mar-26-18Reiterated Goldman Sell $97 → $85
Mar-21-18Resumed JP Morgan Overweight $110
Feb-28-18Reiterated Stifel Buy $130 → $128
Feb-28-18Downgrade SunTrust Buy → Hold
Feb-13-18Upgrade Barclays Equal Weight → Overweight $105
Jan-26-18Reiterated SunTrust Buy $127 → $139
Jan-05-18Downgrade BofA/Merrill Buy → Neutral
Dec-27-17Downgrade Bernstein Outperform → Mkt Perform
Dec-22-17Reiterated Stifel Buy $149 → $130
Feb-18-19 08:48AM  Buy These 5 ROE Stocks Now on Optimism Over Trade Talks Zacks
Feb-17-19 09:00AM  Better Buy: Celgene vs. Gilead Sciences Motley Fool
Feb-16-19 11:16PM  Weekly Top Insider Buys Highlight for the Week of Feb. 15 GuruFocus.com
Feb-15-19 09:09PM  Starboard gauges Bristol-Myers shareholder support for Celgene deal Reuters
04:12PM  Bristol-Myers Squibb Company -- Moody's announces completion of a periodic review of ratings of Bristol-Myers Squibb Company Moody's
02:25PM  Agios (AGIO) Q4 Earnings Beat, Tibsovo Sales Push Up Stock Zacks
02:03PM  Prothena's (PRTA) Q4 Earnings Beat, Revenues Miss Estimates Zacks
01:21PM  This Is One Company That Could Break Up Bristol-Celgene Deal Investor's Business Daily
10:28AM  Alkermes (ALKS) Q4 Earnings & Revenues Surpass Estimates Zacks
09:06AM  Fridays Vital Data: Bristol-Myers Squibb, Intel and Activision Blizzard InvestorPlace
Feb-14-19 01:57PM  Lifshitz & Miller LLP Announces Investigation of Celgene Corporation, SI Financial Group, Inc., Sparton Corporation, Western Gas Partners, LP, Wirecard AG, Yangtze River Port and Logistics Limited, and YRC Worldwide, Inc. PR Newswire
11:55AM  5 Top-Performing Stocks in Nasdaq ETF Zacks
10:08AM  Should You Buy Viking Therapeutics After Gilead Drug Failure? InvestorPlace
07:07AM  Wall Street Rally Gathers Steam in February: 5 Top Picks Zacks
Feb-13-19 11:40AM  Celgene vs. Gilead Stock: Whats the Better Biotech Buy? InvestorPlace
08:36AM  5 Tiny Biotech Stocks With Superb Growth Potential Zacks
Feb-12-19 05:25PM  Health Care Digest: Salesforce's DNA leads deeper into health, a defiant cancer startup and more American City Business Journals
01:53PM  The Biotech Stock Rally May Just Be Getting Started Barrons.com
09:32AM  Take-Two, Las Vegas Sands, Unilever, Rio Tinto and Celgene highlighted as Zacks Bull and Bear of the Day Zacks
Feb-11-19 05:48PM  CELGENE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Celgene Corporation - CELG Business Wire
04:16PM  Why This Patent News Is Big For Bristol's Acquisition Of Celgene Investor's Business Daily
09:39AM  Merrimack (MACK) Stock Up Year to Date: Is a Rebound Likely? Zacks
Feb-10-19 09:00AM  Is Celgene a Buy? Motley Fool
Feb-08-19 03:58PM  Seattle Genetics (SGEN) Q4 Loss Widens, Revenues Top Mark Zacks
02:54PM  [$$] Gormley's Take: Cancer-Drug Startups Generate High Returns---For Now The Wall Street Journal
10:00AM  AMAG Q4 Loss Narrower Than Expected, Revenues Lag Estimates Zacks
Feb-07-19 09:39AM  The Zacks Analyst Blog Highlights: Gilead, Vertex, Celgene, Alkermes and AVEO Zacks
Feb-06-19 10:31AM  Vertex (VRTX) Q4 Earnings Beat on Solid CF Products Sales Zacks
07:06AM  Biotech Stock Roundup: Celgene Tops in Q4, Gilead Disappoints, ALKS & AVEO Sink Zacks
06:36AM  10 Industries That Haven't Been This Cheap in at Least 5 Years Motley Fool
Feb-05-19 05:53PM  Ex-Juno execs lease more than 30,000 square feet in Lake Union life science building American City Business Journals
04:36PM  Activist Investor Urges Allergan To Divide CEO-Chairman Role Investor's Business Daily
01:14PM  Investor Movement Index January Summary Benzinga
07:58AM  Lyfebulb and Celgene Announce Call for Innovation Challenge Applications to Address Unmet Needs in Multiple Sclerosis PR Newswire
Feb-04-19 01:58PM  Celgene Highlights What Bristol-Myers Squibb Is Getting Motley Fool
01:53PM  Bristol-Myers Gains After Starboard Takes a Position Bloomberg
01:20PM  Faber: Hedge fund Starboard Value has not contacted Bristol-Myers Squibb CNBC Videos
12:12PM  5 of the Best Biotech Stocks to Buy Now InvestorPlace
09:18AM  Bristol-Myers Squibb shares pop on report Starboard Value has taken a stake in drugmaker CNBC
03:20AM  Stocks - Papa Johns, Clorox Soar in Premarket, Bristol-Myers, GE, GM Gain Investing.com
01:42AM  Stocks - U.S. Futures Flat Amid Worry Over Slowing Chinese Economy Investing.com
Feb-03-19 09:01AM  The Results Are In, and It's Clear Celgene Doesn't Need Bristol-Myers Squibb Motley Fool
01:22AM  [$$] Wall St set for $1bn fee bonanza from pharma mega-deal Financial Times
Feb-02-19 03:13PM  Starboard Value Is to Take Stake in Bristol-Myers Squibb Bloomberg
Feb-01-19 10:15AM  Pharma Catches Another Case Of M&A Fever Benzinga
09:15AM  Lilly (LLY) Hits 52-Week High, Can the Run Continue? Zacks
08:40AM  Edited Transcript of CELG earnings conference call or presentation 31-Jan-19 2:00pm GMT Thomson Reuters StreetEvents
07:12AM  5 ROE Stocks to Profit Amid Soft Earnings Season Zacks
Jan-31-19 05:23PM  Celgene Takes A Step Closer To Its Bristol Merger With Solid Quarter Investor's Business Daily
03:41PM  Nasdaq Rises, Fueled by Strong Results on Thursday GuruFocus.com
03:15PM  Celgene Corporation (CELG) Q4 2018 Earnings Conference Call Transcript Motley Fool
11:46AM  Celgene (CELG) Q4 Earnings Beat Estimates, Revenues Up Y/Y Zacks
08:55AM  Celgene (CELG) Beats Q4 Earnings and Revenue Estimates Zacks
08:02AM  Celgene: 4Q Earnings Snapshot Associated Press
07:56AM  Celgene profit beats as psoriasis drug sales surge Reuters
07:55AM  Celgene stock up 0.4% after earnings beat MarketWatch
07:37AM  Celgene posts 16 pct rise in fourth quarter revenue Reuters
07:30AM  Celgene Reports Fourth Quarter and Full Year 2018 Operating and Financial Results Business Wire
02:32AM  Celgene Earnings, Revenue beat in Q4 Investing.com
12:36AM  Top 5 Things to Know in The Market on Thursday Investing.com
Jan-30-19 10:02AM  Is a Beat in Store for Vertex (VRTX) This Earnings Season? Zacks
Jan-29-19 10:41AM  Zacks.com featured highlights include: Northrop, Celgene, AVX, WNS and American Axle Zacks
10:00AM  Is a Beat in the Cards for Celgene (CELG) in Q4 Earnings? Zacks
07:55AM  Today's Research Reports on Trending Tickers: Amarin and Celgene ACCESSWIRE
07:15AM  3 Top U.S. Stocks to Watch Motley Fool
05:37AM  PRESS DIGEST- Canada-Jan 29 Reuters
Jan-28-19 04:59PM  Biotech is breaking out. Here's what one analyst says to watch ahead of 3 key earnings reports CNBC
01:38PM  Pfizer Stock Is at Do-or-Die Spot Ahead of Earnings InvestorPlace
08:30AM  5 Stocks Riding High on Relative Price Strength to Buy Now Zacks
04:17AM  Amgen (AMGN) to Report Q4 Earnings: What's in the Cards? Zacks
Jan-27-19 09:03AM  Bristol-Myers Squibb's Q4 Earnings Update Shows Why It Needs Celgene Motley Fool
Jan-26-19 10:05AM  Is Bristol-Myers Squibb a Bargain Now? Motley Fool
06:00AM  Morningstar Runs the Numbers Morningstar
Jan-25-19 05:45PM  Celgene (CELG) Outpaces Stock Market Gains: What You Should Know Zacks
12:00PM  Celgene Stock Is Rising After the CEO of AbbVie Ruled Out a Big Deal Barrons.com
09:30AM  Is Celgene (CELG) Outperforming Other Medical Stocks This Year? Zacks
Jan-24-19 08:38PM  Bristol-Myers Squibb Co (BMY) Q4 2019 Earnings Conference Call Transcript Motley Fool
07:30PM  [$$] Bristol-Myers Reports Higher Sales but Another Lung-Cancer Setback The Wall Street Journal
07:29PM  Can Allergan (AGN) Keep the Earnings Streak Alive in Q4? Zacks
05:04PM  What Happened in the Stock Market Today Motley Fool
05:03PM  [$$] Bristol-Myers Reports Higher Sales but Another Lung-Cancer Setback The Wall Street Journal
04:34PM  Is a Surprise in the Cards for Novartis (NVS) in Q4 Earnings? Zacks
04:23PM  Bristol-Myers Tops Q4 Earnings, Pulls FDA Application for Cancer Combination TheStreet.com
04:14PM  5 Top Stock Trades for Friday: Freeport, Xilinx, Lam Research InvestorPlace
02:20PM  Athersys' (ATHX) MultiStem Cell Therapy Succeeds in Study Zacks
12:58PM  Celgene Buys More of This Biotech Stock Barrons.com
12:21PM  Bristol-Myers has Opdivo lung cancer setback as sales beat estimates Reuters
12:06PM  Bristol-Myers has Opdivo lung cancer setback as sales beat estimates Reuters
11:58AM  Bristol-Myers (BMY) Beats Q4 Earnings, Withdraws Opdivo sBLA Zacks
11:49AM  Bristol-Myers, Celgene deal in focus CNBC Videos
10:51AM  The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio Zacks
10:31AM  Celgene (CELG) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
10:12AM  Where Will bluebird bio Be in 5 Years? Motley Fool
10:08AM  Amicus (FOLD) Boasts Strong Pipeline Amid Stiff Competition Zacks
10:07AM  Bristol-Myers Shares Slide as Cancer-Drug Race Intensifies Bloomberg
09:35AM  Heres Why Bristol-Myers Needs a $74 Billion Shot in the Arm Bloomberg
08:09AM  Bristol-Myers shares fall after it withdraws FDA application for combo lung cancer treatment CNBC
08:00AM  Today's Research Reports on Trending Tickers: Celgene and Gilead Sciences ACCESSWIRE
07:00AM  Bristol-Myers pulls U.S. application for combo lung cancer treatment Reuters
Jan-23-19 05:53PM  Ultragenyx's Fatty Acid Disorder Candidate Succeeds in Study Zacks
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA, a small molecule inhibitor of the isocitrate dehydrogenase 2 to treat acute myeloid leukemia (AML); VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; and THALOMID to treat patients with MM and erythema nodosum leprosum. Its clinical stage products comprise OTEZLA to treat various immune-inflammatory diseases; luspatercept for the treatment of patients with beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; CC-92480 to treat multiple myeloma; and durvalumab, an anti-PD-L1 antibody for hematological cancers. The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Vividion Therapeutics, Inc.; Jounce Therapeutics, Inc.; Prothena Corporation plc; Zymeworks Inc.; and Evotec AG, as well as strategic collaborations with Skyhawk Therapeutics, Inc., Dragonfly Therapeutics, Inc., Obsidian Therapeutics, Philogen S.p.A., and Kyn Therapeutics. The company was founded in 1980 and is headquartered in Summit, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LOUGHLIN JAMES JDirectorFeb 07Option Exercise22.4724,666554,24562,102Feb 11 04:05 PM
LOUGHLIN JAMES JDirectorFeb 07Sale87.2923,4662,048,32438,636Feb 11 04:05 PM
MARIO ERNESTDirectorDec 19Option Exercise59.068,600507,87363,013Dec 20 04:48 PM
Biller JonathanEVP AND GENERAL COUNSELDec 16Option Exercise0.001,90004,046Dec 18 06:45 PM
VESSEY RUPERTSEE REMARKSDec 16Option Exercise0.005,35009,887Dec 18 06:43 PM
Curran TerrieSEE REMARKSDec 16Option Exercise0.002,50009,151Dec 18 06:28 PM
AHMED NADIMPRES., HEMATOLOGY AND ONCOLOGYDec 16Option Exercise0.003,000013,038Dec 18 06:26 PM
Alles Mark JCEO, CHAIRMAN OF BOARDDec 16Option Exercise0.008,9290196,245Dec 18 06:25 PM
MARIO ERNESTDirectorNov 26Option Exercise59.0610,000590,55054,413Nov 28 04:05 PM
MARIO ERNESTDirectorAug 09Sale92.3212,0001,107,88844,413Aug 13 04:05 PM
BARKER RICHARD WDirectorJun 17Option Exercise0.001,000012,846Jun 18 04:00 PM
CASEY MICHAEL DDirectorJun 17Option Exercise0.0033400Jun 18 04:00 PM
Friedman Michael ADirectorJun 17Option Exercise0.0033400Jun 18 04:00 PM
LOUGHLIN JAMES JDirectorJun 17Option Exercise0.00334037,436Jun 18 04:00 PM
MARIO ERNESTDirectorJun 17Option Exercise0.00334056,413Jun 18 04:00 PM
Haller Julia ADirectorJun 15Option Exercise0.0037501,250Jun 15 04:57 PM
MARIO ERNESTDirectorJun 15Option Exercise0.00375056,079Jun 15 04:23 PM
BONNEY MICHAEL WDirectorJun 15Option Exercise0.0037501,050Jun 15 04:17 PM
CASEY MICHAEL DDirectorJun 15Option Exercise0.0037500Jun 15 04:16 PM
LOUGHLIN JAMES JDirectorJun 15Option Exercise0.002,441037,102Jun 15 04:13 PM
Friedman Michael ADirectorJun 15Option Exercise0.002,41300Jun 15 04:12 PM
Haller Julia ADirectorJun 14Option Exercise0.003000875Jun 15 04:57 PM
MARIO ERNESTDirectorJun 14Option Exercise0.00300055,704Jun 15 04:23 PM
BONNEY MICHAEL WDirectorJun 14Option Exercise0.003000675Jun 15 04:17 PM
CASEY MICHAEL DDirectorJun 14Option Exercise0.0030000Jun 15 04:16 PM
LOUGHLIN JAMES JDirectorJun 14Option Exercise0.00300034,661Jun 15 04:13 PM
Friedman Michael ADirectorJun 14Option Exercise0.0030000Jun 15 04:12 PM
COX CARRIE SMITHDirectorJun 12Option Exercise0.006,200030,080Jun 14 04:35 PM
CASEY MICHAEL DDirectorJun 07Option Exercise30.0127,750832,77827,750Jun 11 04:06 PM
CASEY MICHAEL DDirectorJun 07Sale78.7713,0001,024,0100Jun 11 04:06 PM
LOUGHLIN JAMES JDirectorJun 04Option Exercise30.0127,750832,77852,111Jun 05 04:15 PM
LOUGHLIN JAMES JDirectorJun 04Sale78.9617,7501,401,54034,361Jun 05 04:15 PM
Masoudi GeraldSEE REMARKSJun 01Option Exercise0.0015,000020,235Jun 05 04:09 PM
Alles Mark JCEO, CHAIRMAN OF BOARDMay 09Buy82.601,20899,784187,316May 17 04:08 PM
Curran TerrieMay 04Option Exercise0.002,50007,507May 08 04:56 PM
VESSEY RUPERTMay 04Option Exercise0.0078103,731May 08 04:36 PM
KELLOGG PETER NMay 04Option Exercise0.003,500050,831May 08 04:34 PM
Alles Mark JCEO, CHAIRMAN OF BOARDMay 04Option Exercise0.003,5000187,627May 08 04:30 PM
LOUGHLIN JAMES JDirectorMar 12Option Exercise27.189,250251,41533,611Mar 13 04:22 PM
LOUGHLIN JAMES JDirectorMar 12Sale92.019,250851,09324,361Mar 13 04:22 PM
MARIO ERNESTDirectorFeb 23Sale94.4913,3701,263,29855,404Feb 26 04:11 PM
KAPLAN GILLADirectorFeb 20Sale94.839,250877,17876,301Feb 20 05:02 PM